<DOC>
	<DOCNO>NCT01741831</DOCNO>
	<brief_summary>The purpose study assess safety data darunavir natural clinical practice .</brief_summary>
	<brief_title>A Post Marketing Survey Study Evaluate Safety Effectiveness Prezista</brief_title>
	<detailed_description>This non-interventional ( scientific study make clear easy understanding cause effect relationship ) , prospective ( participant first identify follow forward time pass ) , consecutive survey collect safety efficacy data darunavir treatment Acquired Immune Deficiency Syndrome ( AIDS ) natural clinical practice .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Patients prescribed darunavir treatment Acquired Immune Deficiency Syndrome ( AIDS ) Known hypersensitivity Prezista Prezista coadministered medicinal product highly dependent CYP3A clearance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Acquired Immune Deficiency Syndrome</keyword>
	<keyword>AIDS</keyword>
	<keyword>TMC114</keyword>
	<keyword>Darunavir</keyword>
	<keyword>Prezista</keyword>
</DOC>